Catalytic activity of antibodies against factor VIII in patients with hemophilia A

Nature Medicine

Volumn 5, Issue 9, 1999, Pages 1044-1047

  Lacroix Desmazes, Sebastien ^a   Moreau, Alexandre ^a   Sooryanarayana, ^a   Bonnemain, Cécile ^a   Stieltjes, Natalie ^b   Pashov, Anastas ^a   Sultan, Yvette ^b   Hoebeke, Johan ^c   Kazatchkine, Michel D ^a   Kaveri, Srinivas V ^a  

^a INSERM   (France)

^b Hôpital Cochin ^*  (France)

^c INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8;

ANTIGEN ANTIBODY REACTION; ARTICLE; CATALYSIS; HEMOPHILIA A; HUMAN; HUMAN TISSUE; HYDROLYSIS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTIBODIES, CATALYTIC; BINDING, COMPETITIVE; ENDOPEPTIDASES; FACTOR VIII; HEMOPHILIA A; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN G; ISOANTIBODIES; KINETICS; VON WILLEBRAND FACTOR;

EID: 20244363765     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/12483     Document Type: Article

References (25)

1. Ehrenforth, S. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339, 594-598 (1992).
2. Saenko, E.L., Shima, M., Gilbert, G.E. & Scandella, D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for FVIII inhibition. J. Biol. Chem 271, 27424-27431 (1996).
3. Arai, M., Scandella, D. & Hoyer, L.W. Molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J. Clin. Invest. 83, 1978-1984 (1989).
4. Zhong, D., Saenko, E.L., Shima, M., Felch, M. & Scandella, D. Some human inhibitor antibodies interfere with factor VIII binding to Factor IX. Blood 92, 136-142 (1998).
5. Neuenschwander, P.F. & Jesty, J. Thrombin-activated and factor Xa-activated human factor VIII: differences in cofactor activity and decay rate. Arch. Biochem. Biophys. 296, 426-434 (1992).
6. Gilles, J.G.G., Arnout, J., Vermylen, J. & Saint-Remy, J.M. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82, 2452-2461 (1993).
7. Rickard, K.A. Guidelines for therapy and optimal dosages of coagulation factors for treatement of bleeding and surgery in haemophilia. Haemophilia 1, 8-13 (1995).
8. Li, L., Paul, S., Tyutyulkova, S., Kazatchkine, M.D. & Kaveri, S. Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154, 3328-3332 (1995).
9. Gallacher, G. et al. A polyclonal antibody preparation with Michaelian catalytic properties. Biochem. J. 279, 871-881 (1991).
10. Paul, S. et al. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. J Immunol 159, 1530-1536 (1997).
11. Eaton, D.L. et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 25, 8343-8347 (1986).
12. Lollar, P., Knutson, G.J. & Fass, D.N. Activation of porcine factor VIII:C by thrombin and factor Xa. Biochemistry 24, 8056-8064 (1985).
13. Hill-Eubanks, D.C. & Lollar, P. von Willebrand factor is a cofactor for thrombincatalyzed cleavage of factor VIII light chain. J. Biol. Chem. 265, 17854-17858 (1990).
14. O'Brien, D.P., Johnson, D., Byfield, P. & Tuddenham, E.G.D. Inactivation of factor VIII by factor IXa. Biochemistry 31, 2805-2812 (1992).
15. Lamphear, B.J. & Fay, P.J. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa. Blood 80, 3120-3126 (1992).
16. Eaton, D., Rodriguez, H. & Vehar, G.A. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25, 505-512 (1986).
17. Regan, L.M., Lamphear, B.J., Huggins, C.F., Walker, F.J. & Fay, P.J. factor IXa protects factor VIIIa from activated protein C. J. Biol. Chem. 269, 9445-9452 (1994).
18. Koedam, J.A., Meijers, J.C., Sixma, J.J. & Bouma, B.N. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J. Clin. Invest. 82, 1236-1243 (1988).
19. Wion, K.L., Kelly, D., Summerfield, J.A., Tuddenham, E.G. & Lawn, R.M. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317, 726-729 (1985).
20. Leyte, A. et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J. Biol. Chem 266, 740-746 (1990).
21. Paul, S., Volle, D.J., Powell, M.J. & Massey, R.J. Site specificity of a catalytic vasoactive intestinal peptide antibody. J. Biol. Chem. 265, 11910-11913 (1990).
22. Shuster, A.M. et al. DNA hydrolyzing autoantibodies. Science 256, 665-667 (1992).
23. Bronshtein, I.B. et al. DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. FEBS Lett. 314, 259-263 (1992).
24. Kaveri, S. et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J. Clin. Invest. 97, 865-869 (1996).
25. Kasper, C.K., et al, A more uniform measurement of factor VIII inhibitors. Thromb. Diath. Haemorrh. 34, 869-872 (1975).